MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Cost of Revenue 2011-2026 | QTNT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 20.1 M | 17.8 M | 17.2 M | 10.5 M | 10.8 M | 9.66 M | 9.76 M | 8.41 M | 7.17 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.1 M | 7.17 M | 12.4 M |
Quarterly Cost of Revenue Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.9 M | 31.1 M | 27.2 M | - | 7.93 M | 17.6 M | 9.65 M | 5.29 M | 4.97 M | 4.97 M | 4.5 M | 5.41 M | 4.53 M | 4.53 M | 3.97 M | 4.56 M | 4.19 M | 4.19 M | 4.55 M | - | 2.32 M | 2.79 M | 2.83 M | - | 2.6 M | 8.45 M | 5.85 M | - | 2.22 M | 7.1 M | 4.88 M | - | 2.2 M | 7.36 M | 5.16 M | - | 1.94 M | 6.27 M | 4.33 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31.1 M | 1.94 M | 6.65 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
2.91 B | $ 115.35 | -2.33 % | $ 35.1 B |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 12.28 | -2.69 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 22.48 | -1.58 % | $ 234 M |  China |
 |
Bioventus
BVS
|
180 M | $ 8.45 | -7.14 % | $ 563 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 27.23 | -2.44 % | $ 756 M | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 14.59 | 2.41 % | $ 441 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 124.76 | -2.71 % | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
10.9 B | $ 175.33 | -1.8 % | $ 30.1 B | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.11 | -1.36 % | $ 1.41 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 199.8 | -2.07 % | $ 22.2 B | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 195.75 | -2.99 % | $ 140 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.64 B | $ 607.19 | -1.9 % | $ 48.8 B | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | $ 103.5 | 0.17 % | $ 19.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 9.69 | -3.0 % | $ 275 M | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 269.52 | -2.34 % | $ 22.4 B | USA |
 |
DexCom
DXCM
|
1.86 B | $ 68.5 | -3.1 % | $ 26.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 107.08 | -3.19 % | $ 8.83 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
600 M | $ 72.86 | -4.53 % | $ 4.92 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 17.91 | -4.48 % | $ 954 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 5.15 | 0.29 % | $ 477 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 8.92 | -2.3 % | $ 1.14 B | USA |
 |
Guardant Health
GH
|
349 M | $ 91.56 | -1.1 % | $ 11.5 B | USA |
 |
Natera
NTRA
|
158 M | $ 196.94 | -0.1 % | $ 19.4 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
OPKO Health
OPK
|
495 M | $ 1.18 | 0.43 % | $ 819 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |